Stock, pipeline and biotech catalyst intelligence
Market expectations
Street view at a glance
The average target implies 453.8% upsideTargets are estimates—not guarantees—and can change after company updates.Wall Street consensus
Strong BuyBased on 9 analyst opinionsPrice-target range
$17.22Company profile
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.